MYDX News 01/07/2017 - 0.0023

MyDx, Inc. $MYDX News
Last updated 01/07/2017 - 0.0023

MyDx’s OrganaDx and AquaDx Sensors Featured in NBC and ABC Network Television News Reports

Nov 28, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company that has developed MyDx®, the first multi-use handheld chemical analyzer for consumers, today announced that its recently launched OrganaDxTM and AquaDxTM sensors are continuing to capture the attention of major US television broadcast news stations.  This is a direct reflection of both the recent national water crisis as well as the increasing concern amongst consumers that much of our food is being sold with excess amounts of potentially cancer causing pesticides. 

Last Friday, November 25, 2016, NBC Channel 6 News aired a report on MyDx’s OrganaDx sensor. In its report, it cited the organic food industry and its 2015 $43 billion addressable market. It quotes organic farmer Rachel Middleton on camera, “I think if people knew what was really in their food, there is no way that they would want it.”

The report continues to show the reporter validating the OrganaDx sensor’s ability to detect an Organic vs. Non-Organic banana.  It goes on to describe OrganaDx as, “A consumer friendly, food safety test.”

Additionally, after shipping free AquaDx sensors to Florida residents affected by the Mosaic water crisis in Florida, a story published by ABC Action News indicated the water near Mosaic was safe to drink per the US Military Exposure Guideline for Safety standards used by MyDx.  Third party testing lab results that were later reported were in line with MyDx results, indicating the water was safe to drink.  One of MyDx’s core features is that it is able to provide reliable and immediate results as was proven in this case.  

Commenting on the recent nationwide food and water news coverage, Daniel Yazbeck, Chairman and CEO of MyDx said, “The people on our planet are undergoing a massive shift in consciousness with respect to the quality of what they eat, drink and inhale, and MyDx is right where we want to be – enabling newly conscious consumers to make informed choices with real time affordable testing.”  

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Reports Strong Third Quarter 2016 Financial Results

Nov 23, 2016
OTC Disclosure & News Service

-

New Licensing Model to Drive Rapid Earnings Growth and 
Rebuild Shareholder Value in 2017

Third Quarter Highlights:

Changes Business Model with Initial $2.5 Million Licensing Deal 
Company Reduces Operating Cash Burn by 83%
Launches AquaDxTM and OrganaDxTM Sensors
New MyDx Smart Phone App Tops Apple iOS App Store Charts
Anticipates Reaching Positive Cash Flow in Current Quarter
Expects to Enter 2017 with a Strengthened Balance, Poised for Profitability
LA JOLLA, Calif., Nov. 23, 2016 (GLOBE NEWSWIRE) --  MyDx, Inc. (OTCQB:MYDX), a rapidly growing science and technology company that has developed MyDx®, the first multi-use handheld chemical analyzer for consumers, today announced its financial results for the third quarter ended September 30, 2016 and provided guidance that -- fueled in part by its new licensing model -- it expects to reach positive cash flow in the fourth quarter ending December 31, 2016 and achieve profitability in early 2017.

Strong, Third Quarter Operating Results
For the three months ended September 30, 2016 and 2015, the Company had net revenues of $134,240 and $219,180, respectively. The comparable decline in net revenues, year over year, reflects the revenues from CannaDx shipments in 2015 that were a cumulative buildup of nearly one year of pre-sales.  For the three months ended September 30, 2016 and 2015, gross profit as a percentage of net revenues held steady at a healthy 40.2% and 40.8%, respectively.

For the three months ended September 30, 2016, the Company incurred operating expenses in the amount of $1,976,382 compared to $1,447,564 for the three months ended September 30, 2015. In the quarter ended September 30, 2016, the increase in expenses were a direct result of new investments made to create and launch a new global licensing model, with an initial emphasis across the greater China region.  The Company’s licensing deal is expected to generate a minimum of $2.5 million in Earnings over the next 5 years.

On an operating basis, for the nine months ended September 30, 2016, MyDx reported net cash used in operating activities declined approximately 83% to ($698,547) compared with ($4,104,595) in the nine months ended September 30, 2015. For the quarter ended September 30, 2016, MyDx posted a net loss of ($2.87 million) or ($0.08) per share compared with a net loss of ($1.36 million) or ($0.06) per share in the year earlier quarter.

Commenting on the Company’s achievements, Daniel R. Yazbeck, MyDx Chairman and CEO, said, “Over the last nine months, we streamlined our operations across the board, reducing our operating cash burn by 83% year over year, which solidifies our path towards becoming cashflow positive by the end of the fourth quarter and profitable in 2017. 

“During the third quarter, while completing the development, branding and launch of the AquaDx and OrganaDx product lines, we have been working diligently to create, negotiate and close a landmark Asian licensing distribution deal,” he added. “We are pleased to report successfully closing a 5 year $2.5 million high-margin transaction with our first licensing partner in China who will market and distribute the OrganaDx, AquaDx, and AeroDx product lines in that region.”

Q316 Progress: Triples Product Lines and Reaches Top of the iOS Charts

Driven by widespread liberalization of marijuana laws at the state level in the Nov. 8 US Election and a successful test marketing campaign, on November 15, the Company announced its CannaDxTM iOS smartphone app had catapulted to the top of the Apple iOS App Store Charts. This is a major accomplishment following its June 1, launch of its new, feature-rich CannaDxTM smart phone App for both iOS and Android platforms.

In addition to CannaDxTM Sensor launched in late 2015, in recent weeks, the Company has tripled its number of product lines launching two new Sensor Chips for its Analyzer that address major, global mass markets:

On September 15, 2016 MyDx announced the launch the AquaDxTM Sensor to test water for various toxins and heavy metals. As part of its social responsible program, the Company shipped early inventory of it’s single use sensors to affected residents and media in Flint, Michigan, Tampa Florida and other locations with major public health hazards stemming from a contaminated water supply disclosed significantly after its occurrence.  The results were reported in a ABC local action news video link that can be found on our AquaDx sensor page: http://www.cdxlife.com/aqua-sensor/
 
On Oct. 27, MyDx launched its OrganaDxTM Sensor, which tests fruits and vegetables, as well as cannabis (including popular vape oils and edibles) for pesticides and heavy metals.
“We believe 2017 will be a watershed year for MyDx and its shareholders as we expand on our new products launches and licensing model. We extend our sincere thanks to our partners, customers, shareholders and industry advocates for their continued support of our mission,” Mr. Yazbeck concluded.

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

MyDx, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(unaudited)  
   
    September 30,     December 31,  
ASSETS   2016     2015  
             
Current assets:            
Cash   $ 183,752     $ 143,680  
Accounts receivable     40,397       10,702  
Inventory     341,522       451,973  
Prepaid expenses and other current assets     34,264       51,978  
Total current assets     599,935       658,333  
Property and equipment, net     160,516       233,064  
Other assets     87,828       104,365  
Total assets   $ 848,279     $ 995,762  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
                 
Current liabilities:                
Asset based loans   $ 223,497     $ -  
Accounts payable     843,662       619,528  
Customer deposits     56,312       9,467  
Accrued liabilities     1,472,617       281,761  
Current portion of leases payable     2,915       2,773  
Due to related party     1,075       1,075  
Derivative liability     111,048       -  
Convertible notes payable, current     309,649       50,574  
Total current liabilities     3,020,775       965,178  
Long-term liabilities                
Note payable - Related Party     200,000       175,000  
Convertible notes payable     -       200,274  
Other long-term obligations     508       2,721  
Total liabilities     3,221,283       1,343,173  
                 
Commitments and contingencies (Note 11)                
                 
Stockholders' deficit:                
Preferred stock, $0.001 par value, 10,000,000 authorized; zero shares issued as of September 30, 2016 and December 31, 2015, respectively.     -       -  
Common stock, $0.001 par value, 10,000,000,000 shares authorized; 114,620,112 and 22,081,928 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively     114,620       22,081  
Additional paid-in capital     11,757,927       9,528,072  
Accumulated deficit     (14,245,551 )     (9,897,564 )
Total stockholders' deficit     (2,373,004 )     (347,411 )
Total liabilities and stockholders' deficit   $ 848,279     $ 995,762  
                 
  

MyDx, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(unaudited)  
   
    for the three months
ended
September 30,     for the nine months
ended
September 30,  
      2016
      2015
      2016
      2015
 
Net Revenues   $ 134,240     $ 219,180     $ 574,880     $ 219,180  
Cost of goods sold     79,434       131,173       285,123       131,173  
Gross profit     54,806       88,007       289,757       88,007  
Operating Expenses                                
Research and development     111,315       364,370       352,407       1,717,784  
Sales and marketing     1,588,884       203,091       1,792,496       875,744  
General and administrative     276,183       880,103       1,416,440       2,779,156  
Total operating expenses     1,976,382       1,447,564       (3,561,343 )     5,372,684  
Loss from operations     (1,921,576 )     (1,359,557 )     (3,271,586 )     (5,284,677 )
Interest expense, net     807,622       1,051       863,001       442,811  
Change in fair value of derivative liability     (198,338 )     -       (198,338 )     -  
Loss on settlement of debt     335,952       -       409,887       -  
Loss before provision for income taxes     (2,866,812 )     (1,360,608 )     (4,346,136 )     (5,727,488 )
Provision for income taxes     -       575       1,850       1,375  
Net loss   $ (2,866,812 )   $ (1,361,183 )   $ (4,347,986 )   $ (5,728,863 )
                                 
Basic and diluted loss per share   $ (0.08 )   $ (0.06 )   $ (0.15 )   $ (0.35 )
Weighted average shares used in computing net loss per share                                
Basic and diluted     34,235,772       21,845,932       29,750,062       16,601,476  
                                 
 


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



“MyDx One” App Rockets to Top of Apple’s iOS Charts

Nov 15, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing science and technology company that has developed MyDx®, a multi-use handheld chemical analyzer and application, today announced that fueled by last week’s historic passage of state ballot initiatives in eight new states passing cannabis laws, the Company’s “MyDx One” smart-phone app for its Analyzer has catapulted to the top of the iOS App Store charts.  As a direct result, the Company has already experienced an immediate increase in revenues.


MyDx Ranked #1 Medical App in Apple App Store


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab90cdd0-daec-4d16-9b1f-362921526b4d

MyDx One App Tops the Apple iOS Charts
MyDx One is a free app, downloadable with or without owning a multi-use MyDx Analyzer. Even without owning the Analyzer, MyDx One provides users free valuable information to help them find and track cannabis strains and their effectiveness in treating various ailments or producing desired experiences.

As of yesterday, MyDx One was listed as the number one-ranked free app in iOS App Store under the Medical Category (Note: iPhone users, please click on App Store, Top Charts, select Medical Category, Free to view rankings).

As of yesterday, MyDx One was the top trending app in the App Store Search for the keyword “cannabis”.

As of Saturday November 12, 2016, of all the free apps in the iOS App Store, MyDx One was ranked #54, ahead of Google Drive at #55 and just behind Pokémon GO at #53.  

“Our ability to achieve the number one ranking in the Apple Store’s medical category is a clear reflection of the industry’s increasing acceptance of our platform and its unique ability to help consumers identify a strain that meets their needs,” said Daniel Yazbeck, Chairman and Chief Executive Officer of MyDx.  As a result, we are continuing to grow one of the industry’s largest crowdsourced databases with invaluable information that could have only been gathered through the grass roots effort implemented by the CannaDx team since its launch close to one year ago.”

About MyDx, Inc.

MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx CEO Expects Profitability, New Era of Growth and Expansion in Special Letter to Shareholders

Nov 10, 2016
OTC Disclosure & News Service

-

Highlights:

Expects to become cash flow positive in Q416 and profitable in Q117
Expects 2016 revenues to increase by at least 100% over 2015
Company to announce new business model will significantly improve gross margins and earnings going forward
CannaDxTM, as standalone business, generating earnings and nearly $1 million in revenue since commercialization in Q315
Company’s proprietary data positions MyDx to enter into biopharmaceutical industry
Company’s new business model supported by strengthened balance sheet and positive earnings key to driving shareholder value in 2017 and beyond
LA JOLLA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company, today issued the following Special Letter to Shareholders from its Chairman and Chief Executive Officer Daniel Yazbeck.

“Dear Fellow Shareholders,

Before discussing our financial and operational outlook and the impact of this week’s passage of marijuana legalization across eight states, I will first update the goals we set in our June 7, 2016 Shareholder Letter.

MyDx: Meeting 2016 Goals
In that Letter, we outlined three key goals:

New Product Launches. We are now accepting orders for our new OrganaDxTM and AquaDxTM Single Use Sensors – both of which launched and began limited shipping last month in response to the water crises across the nation.

AquaDxTM tests water for various toxins and heavy metals. The recent Flint, Michigan, Alabama and Tampa, Florida water crises have demonstrated that consumers in many cases must rely on themselves to ensure the safety of their water supply. Exemplifying our commitment to be a good corporate citizen, we have shipped some of our early, AquaDx sensor inventory to those area residents affected and their local media at no cost. Analysts forecast the global addressable market for water testing and analysis instruments to be approximately $2.9 billion, and projected to grow at a compound annual growth rate of 5.2% to reach $3.5 billion by 2019.

OrganaDxTM tests fruits and vegetables, as well as cannabis (including popular vape oils and edibles) for pesticides and heavy metals. While cannabis distribution is highly regulated, its safety is not. This should be a major concern to both the industry and the end consumer since pesticides are typically found in much higher concentrations in cannabis than other crops.  However, with this week’s passage of new cannabis initiatives, we expect the demand for cannabis testing, hence the need for OrganaDx, will increase dramatically.

AeroDxTM is entering beta testing shortly in advance of its entry into commercialization in early 2017. Based on the industry’s overwhelming acceptance of our latest sensors, we believe AeroDx will prove to be yet another successful MyDx product line that will immediately contribute to both top and bottom line.

Market Penetration. The market’s adoption of our CannaDx product is a testament to the proprietary technology and innovative approach to testing and tracking we have taken at MyDx. CannaDx continues to capture market share with growers, at legal marijuana dispensaries and hydroponic equipment shops internationally, as well as direct consumers of cannabis products through our online shop and our growing global distribution network. 

Earnings Growth. CannaDx, as a standalone business, is generating earnings and nearly $1 million in revenues since commercialization in Q315. As we have been projecting since the first half of 2016, we expect to become cash flow positive in the current, fourth quarter. Additionally, I will take this opportunity to provide our shareholders with guidance that we expect revenues for our 2016 fiscal year, ending December 31, will increase by at least 100% year-over-year.

Passage of Cannabis Initiatives to Expand MyDx Market Size
On November 8, 2016, America sent two clear messages to the world. Donald Trump will be our new President, and marijuana is here to stay. Cannabis is now legal for adults 21 and over in eight states and the District of Columbia. More than half of all states, 28 in total after Tuesday, allow cannabis for medicinal use. Along with a proliferation of consumers and dispensaries, this will drive an increasing number of home growers as well as far more biopharmaceutical R&D investment into cannabis leading to important new medical breakthroughs.

Ultimately, the cannabis industry will evolve to a level of maturation comparable with the regulated beer and wine markets. Cannabis will become a commodity, so product differentiation will have to come in the form of superior marketing and branding, as well as word-of-mouth adoption of products that can actually deliver a desired feeling or ailment relief, and are free from pesticides.  

MyDx offers consumers the first and only handheld chemical analyzer that tests the safety and chemical profile of cannabis samples, associates them with a feeling and ailment relief, and helps people find a safe strain that works for them. We are very well positioned to support and capitalize on this movement as our products and markets evolve. 

CannaDx Data to Drive Entry into Biopharmaceutical Industry
Major pharmaceutical companies such as Novartis, Pfizer and Roche need to discover, develop and formulate new drugs that must undergo stringent FDA clinical trials which cost on average nearly $300 million. Our CannaDx application, which is HIPAA compliant, collects users’ test data which then can be used to guide cannabis-based drug discovery. MyDx has accumulated over 30,000 unique data points that can significantly accelerate any pharmaceutical company seeking to discover new cannabis-based drugs. We believe this asset alone has more potential than all of our other product lines combined. 

In Summary
While not unusual for a young public company’s stock, the past few weeks have been quite a roller coaster. I, as one of the Company’s largest shareholders, and everyone else working for you here at MyDx, feel your concern and are all the more grateful for your support. Although we might continue to experience some additional pressure from outstanding convertible debentures, I am confident the worst of that turbulence is now behind us and this negative pressure will be offset by a number of positive developments that we have been diligently pursuing over the past year.

These latest developments, when announced, coupled with our stronger financial position will support our outlook for substantially increasing revenue and earnings in 2017 and beyond.

Sincerely,

/s/

Daniel R. Yazbeck
Chairman and Chief Executive Officer
MyDx, Inc.”

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Attending Three November Industry and Investor Conferences; CEO Yazbeck to Present on Cannabis Industry Panel November 16

Oct 31, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and makers of MyDx®, the first handheld chemical analyzer for consumers, today announced it will present at two, high profile investor conferences this month: the Web Summit in Lisbon, Portugal to be held from November 7-10, and the World of Cannabis Summit in Las Vegas from November 15-16.

Additionally, MyDx Chairman and Chief Executive Officer Daniel R. Yazbeck will be attending the ArcView Group meeting November 14-15 in Las Vegas. ArcView is the legal cannabis industry's premier hub for 
investment, data and progress. Mr. Yazbeck is being featured in the new 2016 Cannabis Investor Study co-published and co-produced by ArcView Market Research and New Frontier Data. An investor member since 2013, he is one of only three cannabis company leaders featured with an “Entrepreneur Q&A” interview published in the 55-page Report.

“The Vote Heard Round the Word:” Cannabis Industry Anticipates November 8, Election

These upcoming events hold special importance as the cannabis industry is highly anticipating the November 8, vote in nine States with ballot initiatives to legalize cannabis in some regulatory form, five of whom including California are asking voters to approve recreational use.

The New York Times reports: “The market for both recreational and medicinal marijuana is projected to grow to $22 billion in four years from $7 billion this year if California says yes, according to projections by the ArcView Group, a company that links investors with cannabis companies.

“This is the vote heard round the world,” said ArcView’s chief executive, Troy Dayton. “What we’ve seen before has been tiny compared to what we are going to see in California.”

World of Cannabis Summit, Las Vegas

At the World of Cannabis Summit, MyDx will host a booth on the main exhibitor floor. Also, Mr. Yazbeck will present on the panel titled, “Funding your Business” on November 16, 2016 at 10:00 a.m. PST, where he will be joined by the other two panel members Keith McCarty, CEO and Founder of Eaze, offering a leading cannabis delivery service App which just raised $13 million in its Series B round, and Randy Shipley, President of MJIC, a leader in media and professional services in the cannabis industry.

There, Mr. Yazbeck will share his unique insights and expertise from his success leading MyDx from a crowdfunded startup to rapidly growing public company already nearing positive cash flow.  For more information, visit: http://worldofcannabissummit.com/about/. 

The Company last week announced it has launched its OrganaDx sensor chip. The Company’s CannaDxTM Sensor chip enables consumers to test, analyze and evaluate cannabis for potency and composition of psychoactive, and non-psychoactive medicinal, chemical components. Its newly launched OrganaDx sensor enables consumers to test cannabis for safety. The groundwater under any crop may be contaminated and many growers, both indoor and outdoor, use pesticides or fertilizers that contain dangerous toxins as the media routinely confirms.

Web Summit, Lisbon, Portugal: “Europe’s Largest Technology Marketplace”

Known as “Europe’s Largest Technology Marketplace,” the Web Summit is “home to many independent conferences” (https://websummit.net/). This event provides MyDx a unique opportunity to introduce its growing product line directly to a wide range of prospective partners and customers at the highest levels of industry and technology worldwide.

With over 50,000 tech CEOs, founders, startups, investors and political leaders already booked, a sampling of attending global brand luminaries includes: Facebook CMO Gary Briggs, Groupon CEO Rich Williams, Spotify CMO Seth Farbman, Forbes President Mike Perlis, Burning Man Project Founding Board Member Marian Goodell, Tinder Co-Founder and CEO Sean Rad, and Google Ventures General Partner Tom Hulme. Cannabis Industry attendees include Merry Jane & Stampede Founder and CEO Ted Chung, and Privateer Holdings CEO Brendan Kenney. For a complete list of featured attendees, visit https://websummit.net/speakers. Media covering this event include The Guardian, CNN Money, Bloomberg, Tech Crunch, Time Magazine, Wired Magazine and many others.

MyDx will host a booth in a Web Summit exhibitor hall throughout the conference. MyDx was also selected as 1 of 45 companies (1500+ startups attending) by an Independent Panel of IoT and Hardware Specialists to demonstrate its multi-purpose Analyzer, with smart phone app and its growing line of sensors, to a live audience of key global brands on the Web Summit Machine Demo Stage on Thursday, November 10 at 1:15 p.m. GMT.  

MyDx: Brand Building at the Global Level

At all three conferences, a member of the MyDx team will be available to meet with institutional investors and industry leaders interested in collaborating on global distribution, marketing and other strategic ventures. To schedule a meeting, please contact Phillip Sugarman at Investor Relations Partners, the Company’s IR counsel of record, at 818-280-6800.

About MyDx, Inc.

MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology.

The MyDx CannaDxTM AquaDxTM and OrganaDxTM Sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Launches OrganaDx™ to Test for Pesticides & Heavy Metals in Cannabis and Food for Safety

Oct 27, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and makers of MyDx®, the first handheld chemical analyzer for consumers, today announced it has launched its OrganaDxTM single use sensor chip for the analysis of pesticides and heavy metals in cannabis, fruits and vegetables.  The Company today also released a commercial that will be aired to announce the launch of OrganaDx and increase overall exposure for the Company and the new product line.  The commercial can be seen by visiting the following link:  Launch of OrganaDx Commercial.


OrganaDx Able to Test for Pesticides in Top 10 Crops, Including Cannabis


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/89abcaa7-e284-4a07-a086-e52842d4ad96

OrganaDx: The Next Generation in Consumer Grade Cannabis and Food Safety Testing
OrganaDx puts real-time, affordable analysis in the palms of consumers’ hands.  It enables consumers to detect pesticides or heavy metals in cannabis and food, ensuring that you and your family do not unknowingly consume dangerous cancer-causing toxins at unsafe levels.

OrganaDx enables consumers to test cannabis, or cannabis vape oil, for the same pesticides and heavy metals. According to a report published by Smithsonian.com, “Tests also show that marijuana plants can draw in heavy metals from the soil in which they are grown, and concentrating THC can increase the amounts of heavy metals, pesticides or other substances that end up in a product.”

The Company’s CannaDxTM Sensor chip enables consumers to test, analyze and evaluate cannabis for potency and composition of psychoactive, and non-psychoactive medicinal, chemical components. Its OrganaDx sensor now enables consumers to test cannabis for safety. The groundwater under any crop may be contaminated and many growers, both indoor and outdoor, use pesticides or fertilizers that contain dangerous toxins as the media routinely confirms.

OrganaDx and the Rapidly Growing $6 Billion Cannabis Marketplace
Current polling suggests California is likely to pass its recreational marijuana initiative (Proposition 64) in next month’s election. That, alone, will more than triple the number of U.S. residents living in states where they can buy or grow cannabis without a physician’s recommendation. A total 82 million US residents live in states that could relax rules on cannabis in about two weeks, most of which are expected to pass initiatives permitting recreational or medicinal cannabis.

“Of our product family of four sensors, we launched the CannaDx sensor first,” MyDx Chairman and CEO Daniel R. Yazbeck explained. “Because few states require growers or dispensaries to test the cannabis they sell, the product quality is largely unregulated. This contrasts with water, food and air, all of which have multiple state and federal agencies regulating their quality and anyone that might affect it, although many see their track record as imperfect at best as Flint, Michigan amongst many other incidents exemplifies. Ultimately, it is up to the consumer to Trust & Verify® the safety of what they eat, drink and inhale.

“In the cannabis marketplace, however, very few growers, dispensaries or producers of cannabis flower, distilled concentrate or oil for vape pens obtain and publish independent lab tests for their products potency or safety from poisonous toxins. Today, MyDx receives more inquiries about how to test cannabis for pesticides and heavy metals than it does for food and water combined. To its credit, the media routinely investigates and reports on the prevalence of pesticides and heavy metals in cannabis, especially in the popular THC oil/propellant commonly used in vape pens.”

OrganaDx: $120 Billion TAM and Boost to MyDx Earnings Power
Accordingly, MyDx is confident that consumers pairing the CannaDx and new OrganaDx sensors will drive sales of both products and the multi-use Analyzer. Offering three different Sensor chips enables MyDx customers to leverage the cost of the Analyzer by testing food, water, cannabis composition and cannabis/vape oil safety – all of which multiplies the Analyzer’s utility and value.

Industry analysts project the global organic food and beverage market is expected to grow from $80 billion in 2013 to $162 billion by 2018 for a 15% Compounded Annual Growth Rate (CAGR).1 Further, over 10% of fruits and vegetables sold in the U.S. are organic.2

MyDx’s next-generation OrganaDx technology will empower consumers with the ability to disrupt and increase the marketplace with consumer-based food testing. The OrganaDx Sensor chip will work interchangeably with the multi-use MyDx platform, and, along with CannaDxTM and AquaDxTM, is the third of its four different sensors. Its fourth sensor, AeroDxTM, is designed to measure air quality by monitoring the levels of certain harmful chemicals (VOC’s) in the surrounding environment.  AeroDx is also being programmed to test Cannabis oil for residual solvents.  It is currently in beta stage testing and slated for launch in the first half of 2017.

In addition, MyDx plans to introduce new, digitized versions of its OrganaDx and AquaDx Single Use Sensors that will provide more advanced functionality and customer benefits. Details will be announced in preparation of its launch at a later time.

Why OrganaDx? The Dirty Dozen
Food testing is particularly important when buying non-organic produce that is known to be notoriously high in pesticides, commonly referred to as the “Dirty Dozen” (strawberries top the list). AquaDx tests raw fruits and vegetables for pesticides, heavy metals and other neurotoxic chemicals to the US Military Exposure Guideline (MEG) for safety.

The single-use OrganaDx sensor provides a pass/fail report within six minutes, including an analysis of the toxins tested. Whether you are a consumer who wants to protect your family from foods containing dangerous levels of cancer causing chemicals, or a cannabis dispensary owner who wants to ensure you are not buying or selling contaminated cannabis or THC vape oil, MyDx encourages its customers to use its Analyzer as a primary screening tool. Customers receiving a “fail” test should send the tainted food or cannabis to a commercial laboratory for more granular analysis.

The single-use OrganaDx sensor chips simply require pre-soaking the fruit or vegetable or cannabis in hot water for one minute to leach the chemicals into the water.  The concentrated sample of water with leached chemicals is then applied to the sensor chip with the dropper provided, which will report a PASS or FAIL within 6 minutes.

Commenting on the OrganaDx launch, Mr. Yazbeck said, “Everyone eats fruits and vegetables. Here in the U.S., cancer rates have increased dramatically over the past 50 years and many scientists, researchers and experts, including the Environmental Working Group, have linked the toxic chemicals OrganaDx screens for, to cancer. Raising the stakes, children with developing brains and bodies are typically more at risk other major demographic groups. I live in San Diego, buy fruits and vegetables at local reputable grocers and farmers markets, and yet have purchased strawberries that have failed using our OrganaDx sensor which tested to be tainted with unsafe levels of carcinogens. It is important to spot-check all the fruits and vegetables for my family.”

For an in-depth understanding of why these fruits and vegetables are on the list, and why it is important, please visit the highly respected Environmental Working Group’s recent update on its Dirty Dozen at www.ewg.org/foodnews/summary.php. 

The Next Generation of Consumer-Grade Cannabis and Food Quality Testing
Even if you rigorously wash your produce, there is still a high likelihood that pesticides will have lingered on the surface or may have already seeped into that particular fruit or vegetable. Pesticides have been shown to cause a myriad of adverse effects in humans, including increasing the risk of cancer, impeding neurological development and function, adversely affecting developing fetuses, decreasing fertility, and more. It is, therefore, advisable to purchase organically grown produce and, when possible, to test for these pesticides. Our OrganaDx sensor will allow you to do just that, keeping you and your family safe.

OrganaDx provides its users with a Total Toxicity ProfileTM (TTP), a proprietary rapid response measurement interpretation that reports a TTP of Pass or Fail based on the presence of neurotoxic chemicals in water at concentrations that exceed the US Military Exposure Guideline (MEG) for safety of drinking water (assuming 7-14 day exposure, 15L/day consumption, 70kg person) and are below the estimated Human Lethal Consumption (HLC) guideline. This test covers key organophosphate/carbamate pesticides and toxic heavy metals.  The OrganaDx sensor also detects the most common, highly poisonous Organophosphate Pesticides (such as Malathion, Diazinon and others) that have been linked to Cancer by the World Health Organization (see https://www.cdxlife.com/wp-content/uploads/Mo...me112.pdf).

Ordering OrganaDx
A two-pack Pesticides & Heavy Metals OrganaDx single-use Sensor Kit can be purchased on the MyDx website for only $24.95. The Company anticipates launching new, digital multi-sensor bundled specials in December prior to the holidays.

1 Reportlinker.com; June 2014
2 Organic Trade Association - OTA’s 2014 Organic Industry Survey

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify™ what they put into their minds and bodies. The Company developed MyDx, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established electronic nose technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology.

The MyDx CannaDxTM AquaDxTM and OrganaDxTM Sensors are now commercialized, and the AeroDx is next in line for early 2017. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of everything they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx CEO Sees Emerging Cannabis Industry Attracting Top Tech Talent and Innovation to Sustain Rapid Growth

Oct 17, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and makers of MyDx®, the first handheld chemical analyzer for consumers,  today announced that while speaking as part of a panel, its Chairman and Chief Executive Officer, Daniel R. Yazbeck, noted that due to the cannabis industry’s rapid growth and mainstream acceptance, it is attracting some of the most innovative, high-tech and even traditional senior-level executives in addition to billions of dollars in growth capital.

Mr. Yazbeck was invited to speak on the “Tech Players who Moved into the Cannabis Industry” panel at the New West Summit in San Francisco this past Saturday, October 15, 2016. His panel was followed by keynote speaker and acclaimed entrepreneur, Richard Branson.

Key Highlights of the “Tech Players Who Moved Into Cannabis” Panel

As a clear example of top tech talent and innovation being drawn to the rapidly growing cannabis industry, many executives, including Mr. Yazbeck, made the decision to transition from traditional Fortune 500 executive positions in order to apply their expertise towards the support of the launch and sustainable growth of the cannabis industry.  Prior to founding MyDx, Mr. Yazbeck served as a scientist at Pfizer Pharmaceuticals specializing in chemical R&D technologies, and later as an engineer and strategic new market and business developer for Panasonic before becoming a full-time investor.

As part of Mr. Yazbeck’s remarks, he highlighted how pleased he was with his decision to enter into the cannabis industry, which generated a much higher return on investment, both from a monetary and lifestyle perspective, compared to pursuing a career in more traditional and mature industries such as pharmaceuticals or consumer electronics.

“The excitement and sense of achievement of being able to invent and take CannaDxTM, the first-ever handheld analyzer that detects key chemicals, including THC levels in cannabis, from the lab and into global commercialization, was more satisfying for me than any other career path I could have taken.  MyDx’s success with CannaDx has more importantly proven to us that our products and technology can be applied towards the significantly larger water, air and food industries. 

“We have already seen great interest for our second proprietary chemical sensor, AquaDxTM, which allows consumers to test the safety of their drinking water.  And now we are preparing to launch our third and fourth sensors, OrganaDxTM and AeroDxTM, which test for pesticides in the food we eat and the pollutants in the air we breathe, respectively.  Based on this timeline, it is fairly clear how the growth of the cannabis industry has caused new innovations in technology that have benefited both the cannabis industry as well as other key markets,” concluded Mr. Yazbeck.

About Daniel Yazbeck

Daniel Yazbeck is a leading science, business and technology executive with over 15 years of experience with Fortune 500 companies, including Pfizer and Panasonic.  Mr. Yazbeck holds a Master’s Degree in Medicinal Chemistry with a minor in Marketing, and is an inventor and author of several world patents and research publications. Mr. Yazbeck has been a featured speaker and panelist at cannabis investor, technology and healthcare events over the last three years, and was invited to share the stage with some of the key pioneers and founders of the medical cannabis industry, including Professor Raphael Mechoulam at Cannatech in Israel, who discovered the chemical structures of THC 52 years ago. 

About MyDx, Inc.

MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established technology to measure chemicals of interest. It owns a substantial and growing intellectual property portfolio of patents covering its technology. With its CannaDxTM and AquaDxTM sensors now commercialized, it has two other sensors being developed in its lab that are compatible with the MyDx Analyzer and App that will empower consumers to test the chemical composition of what they eat, drink and inhale.  For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Ships Free AquaDx Sensors to Florida Residents Affected by Water Crisis; New AquaDx Product Line Provides Faster, More Affordable and Convenient Water Safety Analysis

Sep 22, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and the makers of MyDx®, the first multi-use hand-held chemical analyzer for consumers, today announced that in response to the contaminated water crisis in the Tampa, Florida area, it is offering affected area residents free standalone single use AquaDx sensors to test the safety of their drinking water. Residents may call (800) 814-4550 and choose Option 4 to have an AquaDx sensor that reports a Pass or Fail within 6 minutes shipped immediately while supplies last.

A photo accompanying this release is available at
http://www.globenewswire.com/NewsRoom/Attachm...6b614ba8d9


A Single Use AquaDx Sensor


A massive sinkhole at a Mosaic Company fertilizer plant in Mulberry, Florida, has caused about 215 million gallons of toxic water to drain down into the Floridian aquifer system, according to ABC News affiliate WFTS. Mulberry is about 45 minutes east of Tampa, and the aquifer system supplies drinking water to millions of Florida residents, according to the St. Johns Water Management District's website.

Trust and Verify® What You Drink

Fortunately for Central Florida residents, MyDx last week announced it was launching its AquaDx Sensor that works interchangeably with the multi-use, hand-held MyDx Analyzer for the analysis of toxic chemicals in water.  The AquaDx Application is a next-generation system that puts sophisticated water chemical testing and analysis technology, and comprehensive tracking and reporting, in the palm of consumers’ hands conveniently and affordably. MyDx’s AquaDx sensor was recently featured in CNN.   

The MyDx team will now also be offering a standalone single use disposable sensor product line that reports a Pass/Fail to AquaDx customers without the more sophisticated detailed analysis, reporting, and tracking features offered by the digital analyzer.

Commenting on the Mulberry water contamination incident, Daniel R. Yazbeck, MyDx Chairman and CEO, said, “I am sure that various government regulators are doing the best they can to protect the safety of the water supply from contamination that was reported to have begun August 27. In the meantime, days and weeks are far too long to find out if the water your family is drinking is poisonous, or not.

“Fortunately, in parallel to building inventory for our upcoming AquaDx launch, today we have begun shipping our standalone Single Use AquaDx sensors to media and residents affected by the Florida water crisis.

“The simple three step standalone single use sensor is an exciting new product line for MyDx, as it allows us to more quickly and affordably fill the needs of millions of consumers looking to trust and verify the safety of their drinking water. While the media reports the contamination is still spreading, MyDx is especially gratified for the opportunity to provide affected residents with a primary screening tool for harmful toxins in their drinking water today.”

The Next Generation of Consumer-Grade Water Quality Testing 

The AquaDx application offers three different one-time disposable sensors, for:

Pesticides and Heavy Metals (Set to US Military Standards)
Lead (Set to EPA Standards)
Total Hardness, Total Chlorine, pH and Total Alkalinity (Many municipalities use chlorine to “purify” their water. Alkalinity and pH of the body must stay within a narrow range to be healthy.)
MyDx will be shipping the AquaDx sensors that provides its users with a Pass or Fail result based on the presence of neurotoxic chemicals in water at concentrations that exceed the US Military Exposure Guideline (MEG) for safety of drinking water (assuming 7-14 day exposure, 15L/day consumption, 70kg person) and are below the estimated Human Lethal Consumption (HLC) guideline. This test covers key organophosphate/carbamate pesticides and toxic heavy metals. For more info about AquaDx, visit: https://www.cdxlife.com/aqua-sensor/.

About MyDx, Inc.

MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established technology to measure chemicals of interest. It owns a substantial and growing intellectual property portfolio of patents covering its technology. With its CannaDx™ sensor commercialized, it has three other sensors being developed in its lab that are compatible with the MyDx Analyzer and App that will empower consumers to test the chemical composition of everything they eat, drink and inhale.  For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

This photo is also available at Newscom, www.newscom.com, and via AP Photo Express.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Reports Company on Track and on Plan; Conversion, Distribution of Common Stock Temporarily Distorting MyDx Market

Sep 21, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and the makers of MyDx®, the first multi-use hand-held chemical analyzer for consumers, today announced that in response to numerous shareholder inquiries about volatility in the market for its common stock, the Company is reporting its business, sales and new product launches are all on track and on plan.

MyDx expects to report solid revenue for the current, third quarter ending September 30, 2016 while expenses are in line with recent trends as it targets profitability. Its launch of the AquaDxTM Sensor Chip is on schedule with the build-up of inventory on plan for its December 15, 2016 general availability and shipping date.

Previously in 2015 and earlier in 2016, MyDx raised growth capital with convertible debentures, a form of debt which is convertible into common stock. With the Company’s fundamentals better today than ever before and trending toward profitability, debenture holders are inclined to convert now to maximize the number of shares they receive before the MyDx third quarter and fiscal year results are posted. Most debenture holders convert and immediately sell their common stock into the market and when too many sellers try to exit at the same time, the supply can temporarily overwhelm normal demand.

As of September 20, 2016, 52,939,410 common shares were reported to be issued and outstanding, and approximately $500,000 in convertible debt remaining on its balance sheet.  Once that debt is converted, its balance sheet will be strengthened with minimal long term debt remaining.

“Regrettably, it’s a perfect storm, but a temporary one,” said Daniel R. Yazbeck, MyDx Chairman and CEO. “Convertible debenture investors generally are risk adverse and sell immediately upon conversion, creating far more supply than demand for a short time. As the Company’s largest shareholder, I fully understand the concern of our many loyal shareholders.

“Reflecting the gross market distortion, OTC Markets reported that as of September 20, 2016 our Company’s market capitalization, or equity value, is only $714,682 which is equal to the price of a good, publicly traded OTCQB shell company with no operations, products, services, IP or any other assets. One year ago today, as we were just starting to launch the CannaDxTM product line and prior to securing world-class manufacturing, supply chain management and a major US distribution deal, our market cap was approximately $28 million -- or about 40 times that of yesterday’s closing value.

“Today,” Mr. Yazbeck concluded, “CannaDx is a proven seller with a clear ramp up. AquaDx is in launch phase, while the OrganaDxTM and AeroDxTM product lines are being readied for launch shortly. Further, MyDx has been working for months on several major new business and marketing initiatives that we anticipate closing and announcing shortly.”

About MyDx, Inc.
MyDx, Inc. (MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established technology to measure chemicals of interest. It owns a substantial and growing intellectual property portfolio of patents covering its technology. With its CannaDx™ sensor commercialized, it has three other sensors being developed in its lab that are compatible with the MyDx Analyzer and App that will empower consumers to test the chemical composition of everything they eat, drink and inhale.  For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



MyDx Launching AquaDx Sensor to Test for Harmful Chemicals in Water; Company Accepting Pre-Orders for December Delivery

Sep 15, 2016
OTC Disclosure & News Service

-

LA JOLLA, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company and the makers of MyDx®, the first multi-use hand-held chemical analyzer for consumers, today announced it is launching its AquaDx™ sensor chip for the analysis of toxic chemicals in water, and is now accepting pre-orders at special pricing for early adopters.  The AquaDx Sensor works interchangeably with the MyDx Analyzer and, along with the CannaDx™ sensor, is the second of its four different sensors -- with OrganaDx™ (tests organic fruits and vegetables) and AeroDx™ (tests air quality) both in beta stage and also slated for launch in the coming months.


AquaDx Sampling Procedure.


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/11ea6172-051c-4c84-8a08-42e7a004919f

MyDx Early Adopters Win 
For a limited time, the Company is running a special AquaDx pre-order promotion. New MyDx customers ordering the multi-use Analyzer and AquaDx Electronic Sensor Chip will receive a $100 discount, plus ten free single-use AquaDx sensors and free shipping and handling. Existing MyDx Analyzer owners will receive the AquaDx Electronic Sensor Chip plus ten free single-use AquaDx sensors and a free Multi-Use retrofit upgrade kit ($99 value) and free shipping and handling, for $69.95.  AquaDx delivery is scheduled for December 15. For more info about AquaDx and pre-order details, visit: https://www.cdxlife.com/aqua-sensor/. 

MyDx Analyzer Applications Growing: AquaDx Addresses $3 Billion Growth Market
The global addressable market for water testing and analysis instruments is approximately $2.9 billion, and projected to grow at compound annual growth rate of 5.2% to reach $3.5 billion by 2019. By putting sophisticated water chemical test and analysis technology in the palm of consumers’ hands, conveniently and affordably, the Company expects its next-generation AquaDx technology will disrupt and significantly expand the global marketplace for water testing.

The Next Generation of Consumer-Grade Water Quality Testing
Just as it does for the CannaDx sensor, the MyDx Analyzer connects the AquaDx sensor by Bluetooth to a smart phone app (iOS and Android) that uploads and aggregates big data analytics and downloads a comprehensive report to the consumer within minutes. The AquaDx application will offer three different one-time disposable sensors, for:

Pesticides and Heavy Metals (Set to US Military Standards)
Lead (Set to EPA Standards, Think Flint Michigan water health crisis)
Total Hardness, Total Chlorine, pH and Total Alkalinity (Many municipalities use chlorine to “purify” their water. Alkalinity and pH of the body must stay within a narrow range to be healthy and accordingly, in recent years, the scientific community places increasing importance on the alkalinity of the food and water we consume.)
AquaDx features include:

Real-time detection of toxic chemicals in drinking water
Tests for pesticides, heavy metals and other neurotoxin chemicals to the US Military Exposure Guideline (MEG) for Safety
Easy to use, pass/fail results within six minutes
Handheld, battery operated, fits in your back pocket
Track your data, share on social media, print results
AquaDx provides its users with a Total Toxicity Profile™ (TTP), a proprietary measurement that reports a Pass or Fail based on the presence of neurotoxic chemicals in water at concentrations that exceed the US Military Exposure Guideline (MEG) for drinking water (assuming 7-14 day exposure, 15L/day consumption, 70kg person) and are below the estimated Human Lethal Consumption (HLC) guideline. This test covers key organophosphate/carbamate pesticides and toxic heavy metals.

Dramatic Boost to Earnings Power and Ensuring Safe Water for All
Commenting on the AquaDx launch, Daniel R. Yazbeck, MyDx Chairman and CEO, said, “Unlike our popular CannaDx analyzer, which addresses a rapidly growing $5 billion legal cannabis market whose product quality is largely unregulated, the AquaDx analyzer potentially addresses everyone on the planet who drinks water.

“The Flint Michigan poisoned water health crisis is only the most recent and highly publicized incident of its type; there are many others,” he added. See the July 28, CNN article featuring MyDx on this subject at: http://money.cnn.com/2016/07/28/technology/wa...index.html.

“While AquaDx is highly anticipated to provide a dramatic increase to our earnings power, this launch is especially gratifying for myself and all MyDx employees at a personal level given that everyone, worldwide, should have access to clean, safe drinking water. AquaDx will empower consumers to test their water safety in a simple and practical way,” Mr. Yazbeck concluded. “I invite all MyDx shareholders to share in the pride and satisfaction of helping to commercialize the important health benefit our AquaDx will provide consumers globally.”

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established technology to measure chemicals of interest. It owns a substantial and growing intellectual property portfolio of patents covering its technology. With its CannaDx™ sensor commercialized, it has three other sensors being developed in its lab that are compatible with the MyDx Analyzer and App that will empower consumers to test the chemical composition of everything they eat, drink and inhale.  For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.


Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com


Copyright © 2016 GlobeNewswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.